Below is a listing of recently published scientific papers authored by our staff.

2019

Improving Molecular Oncology by Making Results Available to Patients.
Oxnard GR, West H, King JC
JAMA Oncol. Epub October 24, 2019. doi:10.1001/jamaoncol.2019.4390

Effectiveness of Lung Cancer Screening Implementation in the Community Setting in the United States.
Copeland A, Criswell A, Ciupek A, King JC.
J Oncol Pract. 2019 Jul;15(7):e607-e615. doi: 10.1200/JOP.18.00788. Epub 2019 May 31.

Updates Regarding Biomarker Testing for Non-Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable.
Kim ES, Roy UB, Ersek JL, King J, Smith RA, Martin N, Martins R, Moore A, Silvestri GA, Jett J.
J Thorac Oncol. 2019 Mar;14(3):338-342.

Survivor guilt: The secret burden of lung cancer survivorship.
Perloff T, King JC, Rigney M, Ostroff JS, Shen MJ
J Psychosoc Oncol. 2019 Sep-Oct;37(5):573-585.

2018

The Role of Lung Advocacy Organizations in Biomarker Testing
Aldigé C, Roy U, Boerckel W, Ciupek A, Donaldson D, Grossman H, Langhorne C, Rosenthal LS, Saxton C, Silvestri GA, Smith RA, and Wenger L
White Paper

Geographic Availability of Low-Dose Computed Tomography for Lung Cancer Screening in the United States, 2018.
Eberth JM, Bozorgi P, Lebrón LM, Bills SE, Hazlett LJ, Carlos RC, King JC.
Prev Chronic Dis. 2018 Oct 4;15:E119.

Patient value: Perspectives from the advocacy community.
Addario BJ, Fadich A, Fox J, Krebs L, Maskens D, Oliver K, Schwartz E, Spurrier-Bernard G, Turnham T.
Health Expect. 2018 Feb;21(1):57-63.

2017

Patient engagement is mandatory at our table.
Addario BJ, Pritchard D.
Am J Manag Care. 2017 Aug;23(10 Spec No.):SP431-SP432

Decreasing Lung Cancer Mortality through Screening—The Lung Cancer Alliance Experience
Ambrose LF, Copeland A, King JC.
Oncology & Hematology Review, 2017;13(1):17–8

Stigma, self-blame, and satisfaction with care among patients with lung cancer.
Weiss J, Yang H, Weiss S, Rigney M, Copeland A, King JC, Deal AM.
J Psychosoc Oncol. 2017 Mar-Apr;35(2):166-179.

2016

Implementing computed tomography-based lung cancer screening in the community.
Mulshine JL, Ambrose LF.
J Thorac Dis. 2016 Oct;8(10):E1304-E1306.

Planning and Implementation of Low-Dose Computed Tomography Lung Cancer Screening Programs in the United States.
Qiu R, Copeland A, Sercy E, Porter NR, McDonnell KK, Eberth J.
Clin J Oncol Nurs. 2016 Feb;20(1):52-8.

Readiness of Lung Cancer Screening Sites to Deliver Smoking Cessation Treatment: Current Practices, Organizational Priority, and Perceived Barriers.
Ostroff JS, Copeland A, Borderud SP, Li Y, Shelley DR, Henschke CI.
Nicotine Tob Res. 2016 May;18(5):1067-75.

2015

A Qualitative Analysis of “Naturalistic” Conversations in a Peer-Led Online Support Community for Lung Cancer.
Lobchuk M, McClement S, Rigney M, Copeland A, Bayrampour H.
Cancer Nurs. 2015 Sep-Oct;38(5):E21-31.

Lung Cancer Workshop XI: Tobacco-Induced Disease: Advances in Policy, Early Detection and Management.
Mulshine JL, Avila R, Yankelevitz D, Baer TM, Estépar RS, Ambrose LF, Aldigé CR.
J Thorac Oncol. 2015 May;10(5):762-7.

2014

Preventative care: Lung-cancer screens now worth the cost.
Fenton-Ambrose L, Kazerooni EA
Nature. 2014 Oct 2;514(7520):35.

Public attitudes about lung cancer: stigma, support, and predictors of support.
Weiss J, Stephenson BJ, Edwards LJ, Rigney M, Copeland A.
J Multidiscip Healthc. 2014 Jul 16;7:293-300.

.